论文部分内容阅读
70年代起干扰素(Interferon.IFN)进入抗癌临床试验,当时使用细胞中提取的不很纯的天然IFN,价贵难得,影响了试验的进程。近年来,发展了基因重组的高度纯化的IFN。这不仅可提供足量以进行大规模临床试验,而且使我们了解到有多种不同的品种。重组IFN-alfa-2a是从1981年起进行临床试验,业已证明对造血系统肿瘤,尤其毛细胞白血病有显著疗效。于1985年6月在日本大阪召开了重组IFN治疗恶性肿瘤的进展会议。学术论文集中发表于1986年4月的Cancer杂志(57卷8期),现特将有关资料整理综合如下。 Trown PW等进行了临床前研究,证明在人的Ag1732细胞中IFN对鼻病毒、单疱疹病毒、Semliki森林病毒、脑炎、心肌
Interferon (IFN) entered anticancer clinical trials in the 1970s, when the use of less pure natural IFNs extracted from cells was expensive, affecting the course of the trial. In recent years, genetically recombinant highly purified IFNs have been developed. This not only provides sufficient quantities for large-scale clinical trials, but also allows us to understand that there are many different varieties. Recombinant IFN-alfa-2a has been clinically tested since 1981 and has been shown to have a significant effect on hematopoietic tumors, especially hairy cell leukemia. In June 1985, a meeting on the progress of recombinant IFN therapy for malignant tumors was held in Osaka, Japan. The academic papers were published in the 1986 issue of Cancer magazine (Volume 57, Issue 8). Trown PW et al. performed a preclinical study demonstrating that IFN interacts with rhinovirus, herpes simplex virus, Semliki forest virus, encephalitis, and myocardium in human Ag1732 cells.